ProCE Banner Activity

New Data on COVID-19 Treatment and Risk Factors for Severe Breakthrough Infections Post Vaccination

Clinical Thought

Many interesting COVID-19 presentations were delivered at IDWeek 2022, but I found 2 studies particularly relevant for clinical practice—an analysis of risk factors for severe breakthrough infections and a secondary endpoint analysis of the randomized EPIC-HR study in those at high risk for severe disease.

Released: November 17, 2022

Share

Faculty

Gregory Huhn

Gregory Huhn, MD, MPHTM

Professor of Medicine
Department of Infectious Diseases
Rush University Medical Center
Interim Chief
Division of Infectious Diseases
Cook County Health
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Gregory Huhn, MD, MPHTM

Professor of Medicine
Department of Infectious Diseases
Rush University Medical Center
Interim Chief
Division of Infectious Diseases
Cook County Health
Chicago, Illinois

Gregory Huhn, MD, MPHTM: consultant/advisor/speaker: CME Outfitters, Gilead Sciences, Integritas, Janssen, Lilly, Medscape, Merck, Rockpointe, ViiV Healthcare; researcher: Gilead Sciences, Janssen, Lilly, ViiV Healthcare.